Back to discover
Disease

Ulcer

Late-stage therapeutic developmentEmerging research
MeSHUlcer
1
Publications
24
Clinical trials
9
Associated genes
1
Related proteins
2017
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Update of EULAR recommendations for the treatment of systemic sclerosis.

Research2016-11-09Annals of the rheumatic diseases

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 3 clinical trials expected to report results, the earliest in Q1 2027.
  • 1 industry development reported.
Upcoming Milestones
Clinical Milestones5View
Results expected 3
Recently completed 2
Industry & Market1View
Activity timeline6

Clinical trials

15 sponsors · 3 new · 0 completed in the last 12 months (net +3)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
16
Late-stage
6
Completed
Late-stage studies

The SEMAFOOT2 Pilot Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients

Phase 3 · Recruiting · Ole Lander Svendsen

A Pivotal, Randomized, Placebo-controlled, Double-blind, Multicenter, International Phase III Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Non-Healing Chronic Venous Ulcers (CVU)

Phase 3 · Active, not recruiting · RHEACELL GmbH & Co. KG

A Non-Randomized Open Label Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of DermaBind TL, a Placental Membrane Allograft Intended for Use in the Management of Non-Healing Ulcers

Phase 4 · Recruiting · HealthTech Wound Care

Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?

Phase 4 · Active, not recruiting · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

A Phase II/III Seamless Design, Randomized, Double-blind, Paralleled-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers

Phase 2/3 · Active, not recruiting · Oneness Biotech Co., Ltd.

A Multicenter Phase 3 Confirmatory Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

Phase 3 · Completed · BioTissue Holdings, Inc
Recently completed

A Multicenter Phase 3 Confirmatory Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

Phase 3 · Completed · BioTissue Holdings, Inc

A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of HIP0612 in Patients With Gastric Ulcer

Phase 3 · Completed · Hanmi Pharmaceutical Company Limited

Phase 3 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers: A Randomized, Comparator-controlled, Double-blind, Parallel-group, Multi-center Study

Phase 3 · Completed · Anterogen Co., Ltd.

Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)

Phase 3 · Completed · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Phase 4 · Completed · Yongquan Shi

Beta Adrenergic Antagonist For The Healing of Chronic Diabetic Foot Ulcers

Phase 3 · Completed · VA Office of Research and Development

Evidence coverage

8 treatments

How much of this condition's readable clinical evidence the confidence engine has incorporated, across its most-studied treatments. This measures coverage of the evidence base — not whether any treatment works.

Minimal evidence coverage
16% · 4/25 eligible items incorporated

Largest gap: no meaningful change (12, trial-readability).

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Update of EULAR recommendations for the treatment of systemic sclerosis.

Annals of the rheumatic diseases · 2017 · 708 cites
Recent publications

Update of EULAR recommendations for the treatment of systemic sclerosis.

Annals of the rheumatic diseases · 2017 · 708 cites
Leading journals1
  • Annals of the rheumatic diseases1
Leading researchers8
  • Allanore Y1
  • Avouac J1
  • Becker M1
  • Clements P1
  • Cutolo M1
  • Czirjak L1
  • Damjanov N1
  • Del Galdo F1
Affiliations (unnormalised)6
  • Basel University1
  • Central Manchester NHS Foundation Trust1
  • Cochin Hospital1
  • Department of Rheumatology and Clinical Immunology1
  • Ghent University Hospital1
  • Hamburg Centre for Pediatric and Adolescence Rheumatology1

Associated genes

9 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

HRH20.47IL100.43TNRC180.39MST10.37CCR10.30OTUD30.21APEH0.10TMCO40.09OMP0.05

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Interleukin-10via IL100.43

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.

Identifiers
MeSHUlcer
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.